Antibiotic resistance mechanisms of clinically important bacteria

Bacterial resistance to antimicrobial drugs is an increasing health and economic problem. Bacteria may be innate resistant or acquire resistance to one or few classes of antimicrobial agents. Acquired resistance arises from: (i) mutations in cell genes (chromosomal mutation) leading to cross-resista...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicina (Kaunas, Lithuania) Lithuania), 2011-01, Vol.47 (3), p.137-146
Hauptverfasser: Giedraitienė, Agnė, Vitkauskienė, Astra, Naginienė, Rima, Pavilonis, Alvydas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 146
container_issue 3
container_start_page 137
container_title Medicina (Kaunas, Lithuania)
container_volume 47
creator Giedraitienė, Agnė
Vitkauskienė, Astra
Naginienė, Rima
Pavilonis, Alvydas
description Bacterial resistance to antimicrobial drugs is an increasing health and economic problem. Bacteria may be innate resistant or acquire resistance to one or few classes of antimicrobial agents. Acquired resistance arises from: (i) mutations in cell genes (chromosomal mutation) leading to cross-resistance, (ii) gene transfer from one microorganism to other by plasmids (conjugation or transformation), transposons (conjugation), integrons and bacteriophages (transduction). After a bacterium gains resistance genes to protect itself from various antimicrobial agents, bacteria can use several biochemical types of resistance mechanisms: antibiotic inactivation (interference with cell wall synthesis, e.g., β-lactams and glycopeptide), target modification (inhibition of protein synthesis, e.g., macrolides and tetracyclines; interference with nucleic acid synthesis, e.g., fluoroquinolones and rifampin), altered permeability (changes in outer membrane, e.g., aminoglycosides; new membrane transporters, e.g., chloramphenicol), and "bypass" metabolic pathway (inhibition of metabolic pathway, e.g., trimethoprim-sulfamethoxazole).
doi_str_mv 10.3390/medicina47030019
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_893265663</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>893265663</sourcerecordid><originalsourceid>FETCH-LOGICAL-c270t-234f95c900acb28c724be39f485791c7c87db6b9e57dd73a0ed44234ddd4aa2c3</originalsourceid><addsrcrecordid>eNpdkDtPwzAUhS0EoqWwM6FsTIHrR-J4jCoKSJVYYI7sa0cY5VFsZ-i_J6gFIaZ7pPt9ZziEXFO441zBfe-sRz9oIYEDUHVClrQUVa6oEKd_8oJcxPgBwFkh2TlZMFoxBrxYkroekjd-TB6z4KKPSQ_ost7hux587GM2thl2fvCou26f-X43hplJmdGYXPD6kpy1uovu6nhX5G3z8Lp-yrcvj8_repsjk5ByxkWrClQAGg2rUDJhHFetqAqpKEqspDWlUa6Q1kquwVkhZslaK7RmyFfk9tC7C-Pn5GJqeh_RdZ0e3DjFplKclUVZ8pmEA4lhjDG4ttkF3-uwbyg037s1_3eblZtj-WTm56_wMxT_AtKFa3Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>893265663</pqid></control><display><type>article</type><title>Antibiotic resistance mechanisms of clinically important bacteria</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Giedraitienė, Agnė ; Vitkauskienė, Astra ; Naginienė, Rima ; Pavilonis, Alvydas</creator><creatorcontrib>Giedraitienė, Agnė ; Vitkauskienė, Astra ; Naginienė, Rima ; Pavilonis, Alvydas</creatorcontrib><description>Bacterial resistance to antimicrobial drugs is an increasing health and economic problem. Bacteria may be innate resistant or acquire resistance to one or few classes of antimicrobial agents. Acquired resistance arises from: (i) mutations in cell genes (chromosomal mutation) leading to cross-resistance, (ii) gene transfer from one microorganism to other by plasmids (conjugation or transformation), transposons (conjugation), integrons and bacteriophages (transduction). After a bacterium gains resistance genes to protect itself from various antimicrobial agents, bacteria can use several biochemical types of resistance mechanisms: antibiotic inactivation (interference with cell wall synthesis, e.g., β-lactams and glycopeptide), target modification (inhibition of protein synthesis, e.g., macrolides and tetracyclines; interference with nucleic acid synthesis, e.g., fluoroquinolones and rifampin), altered permeability (changes in outer membrane, e.g., aminoglycosides; new membrane transporters, e.g., chloramphenicol), and "bypass" metabolic pathway (inhibition of metabolic pathway, e.g., trimethoprim-sulfamethoxazole).</description><identifier>ISSN: 1648-9144</identifier><identifier>EISSN: 1648-9144</identifier><identifier>DOI: 10.3390/medicina47030019</identifier><identifier>PMID: 21822035</identifier><language>eng</language><publisher>Switzerland</publisher><subject>Anti-Bacterial Agents - metabolism ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Bacteria - classification ; Bacteria - drug effects ; Bacterial Infections - drug therapy ; Bacterial Infections - microbiology ; Cell Membrane Permeability ; Drug Resistance, Bacterial</subject><ispartof>Medicina (Kaunas, Lithuania), 2011-01, Vol.47 (3), p.137-146</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c270t-234f95c900acb28c724be39f485791c7c87db6b9e57dd73a0ed44234ddd4aa2c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21822035$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giedraitienė, Agnė</creatorcontrib><creatorcontrib>Vitkauskienė, Astra</creatorcontrib><creatorcontrib>Naginienė, Rima</creatorcontrib><creatorcontrib>Pavilonis, Alvydas</creatorcontrib><title>Antibiotic resistance mechanisms of clinically important bacteria</title><title>Medicina (Kaunas, Lithuania)</title><addtitle>Medicina (Kaunas)</addtitle><description>Bacterial resistance to antimicrobial drugs is an increasing health and economic problem. Bacteria may be innate resistant or acquire resistance to one or few classes of antimicrobial agents. Acquired resistance arises from: (i) mutations in cell genes (chromosomal mutation) leading to cross-resistance, (ii) gene transfer from one microorganism to other by plasmids (conjugation or transformation), transposons (conjugation), integrons and bacteriophages (transduction). After a bacterium gains resistance genes to protect itself from various antimicrobial agents, bacteria can use several biochemical types of resistance mechanisms: antibiotic inactivation (interference with cell wall synthesis, e.g., β-lactams and glycopeptide), target modification (inhibition of protein synthesis, e.g., macrolides and tetracyclines; interference with nucleic acid synthesis, e.g., fluoroquinolones and rifampin), altered permeability (changes in outer membrane, e.g., aminoglycosides; new membrane transporters, e.g., chloramphenicol), and "bypass" metabolic pathway (inhibition of metabolic pathway, e.g., trimethoprim-sulfamethoxazole).</description><subject>Anti-Bacterial Agents - metabolism</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Bacteria - classification</subject><subject>Bacteria - drug effects</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacterial Infections - microbiology</subject><subject>Cell Membrane Permeability</subject><subject>Drug Resistance, Bacterial</subject><issn>1648-9144</issn><issn>1648-9144</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkDtPwzAUhS0EoqWwM6FsTIHrR-J4jCoKSJVYYI7sa0cY5VFsZ-i_J6gFIaZ7pPt9ZziEXFO441zBfe-sRz9oIYEDUHVClrQUVa6oEKd_8oJcxPgBwFkh2TlZMFoxBrxYkroekjd-TB6z4KKPSQ_ost7hux587GM2thl2fvCou26f-X43hplJmdGYXPD6kpy1uovu6nhX5G3z8Lp-yrcvj8_repsjk5ByxkWrClQAGg2rUDJhHFetqAqpKEqspDWlUa6Q1kquwVkhZslaK7RmyFfk9tC7C-Pn5GJqeh_RdZ0e3DjFplKclUVZ8pmEA4lhjDG4ttkF3-uwbyg037s1_3eblZtj-WTm56_wMxT_AtKFa3Y</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Giedraitienė, Agnė</creator><creator>Vitkauskienė, Astra</creator><creator>Naginienė, Rima</creator><creator>Pavilonis, Alvydas</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110101</creationdate><title>Antibiotic resistance mechanisms of clinically important bacteria</title><author>Giedraitienė, Agnė ; Vitkauskienė, Astra ; Naginienė, Rima ; Pavilonis, Alvydas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c270t-234f95c900acb28c724be39f485791c7c87db6b9e57dd73a0ed44234ddd4aa2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Anti-Bacterial Agents - metabolism</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Bacteria - classification</topic><topic>Bacteria - drug effects</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacterial Infections - microbiology</topic><topic>Cell Membrane Permeability</topic><topic>Drug Resistance, Bacterial</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giedraitienė, Agnė</creatorcontrib><creatorcontrib>Vitkauskienė, Astra</creatorcontrib><creatorcontrib>Naginienė, Rima</creatorcontrib><creatorcontrib>Pavilonis, Alvydas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medicina (Kaunas, Lithuania)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giedraitienė, Agnė</au><au>Vitkauskienė, Astra</au><au>Naginienė, Rima</au><au>Pavilonis, Alvydas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotic resistance mechanisms of clinically important bacteria</atitle><jtitle>Medicina (Kaunas, Lithuania)</jtitle><addtitle>Medicina (Kaunas)</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>47</volume><issue>3</issue><spage>137</spage><epage>146</epage><pages>137-146</pages><issn>1648-9144</issn><eissn>1648-9144</eissn><abstract>Bacterial resistance to antimicrobial drugs is an increasing health and economic problem. Bacteria may be innate resistant or acquire resistance to one or few classes of antimicrobial agents. Acquired resistance arises from: (i) mutations in cell genes (chromosomal mutation) leading to cross-resistance, (ii) gene transfer from one microorganism to other by plasmids (conjugation or transformation), transposons (conjugation), integrons and bacteriophages (transduction). After a bacterium gains resistance genes to protect itself from various antimicrobial agents, bacteria can use several biochemical types of resistance mechanisms: antibiotic inactivation (interference with cell wall synthesis, e.g., β-lactams and glycopeptide), target modification (inhibition of protein synthesis, e.g., macrolides and tetracyclines; interference with nucleic acid synthesis, e.g., fluoroquinolones and rifampin), altered permeability (changes in outer membrane, e.g., aminoglycosides; new membrane transporters, e.g., chloramphenicol), and "bypass" metabolic pathway (inhibition of metabolic pathway, e.g., trimethoprim-sulfamethoxazole).</abstract><cop>Switzerland</cop><pmid>21822035</pmid><doi>10.3390/medicina47030019</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1648-9144
ispartof Medicina (Kaunas, Lithuania), 2011-01, Vol.47 (3), p.137-146
issn 1648-9144
1648-9144
language eng
recordid cdi_proquest_miscellaneous_893265663
source MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals
subjects Anti-Bacterial Agents - metabolism
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Bacteria - classification
Bacteria - drug effects
Bacterial Infections - drug therapy
Bacterial Infections - microbiology
Cell Membrane Permeability
Drug Resistance, Bacterial
title Antibiotic resistance mechanisms of clinically important bacteria
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T07%3A25%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotic%20resistance%20mechanisms%20of%20clinically%20important%20bacteria&rft.jtitle=Medicina%20(Kaunas,%20Lithuania)&rft.au=Giedraitien%C4%97,%20Agn%C4%97&rft.date=2011-01-01&rft.volume=47&rft.issue=3&rft.spage=137&rft.epage=146&rft.pages=137-146&rft.issn=1648-9144&rft.eissn=1648-9144&rft_id=info:doi/10.3390/medicina47030019&rft_dat=%3Cproquest_cross%3E893265663%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=893265663&rft_id=info:pmid/21822035&rfr_iscdi=true